| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
2 |
16 |
0.25 － >32 |
Ceftriaxone (Rocephin)  |
102 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
2 |
16 |
0.5 － 128 |
Ampicillin (Omnipen) |
1464 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
4 |
64 |
≤0.12 － 128 |
Piperacillin (Pipracil) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
8 |
32 |
8 － 64 |
Mannopeptimycins (γ) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
16 |
32 |
8 － >128 |
D-ofloxacin |
117 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
64 |
64 |
4 － 128 |
Thymol |
1464 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
0.12 |
? － ? |
Ceftaroline |
1358 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
1.5 |
? － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
1112 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
2 |
? － ? |
Linezolid (PNU-100766, U-100766, Zyvox) |
1358 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
4 |
? － ? |
Daptomycin (Cubicin) |
1358 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
16 |
4 － 32 |
Mannopeptimycins (δ) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
0.25 － 0.5 |
RWJ-416457 |
280 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
0.5 － 1 |
Linezolid (PNU-100766, U-100766, Zyvox) |
280 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
0.5 － 1 |
Linezolid (PNU-100766, U-100766, Zyvox) |
193 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
0.5 － 1 |
Vancomycin (Vancocyn, Lyphocin) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
1 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
193 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
1 － ? |
PH-027 |
193 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
2 － 4 |
Mannopeptimycins (ε) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
2 － 8 |
Mannopeptimycins (δ) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
4 － 8 |
Mannopeptimycins (γ) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
32 － 128 |
Mannopeptimycins (β) |
89 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
- |
- |
64 － >128 |
Mannopeptimycins (α) |
89 |
| Staphylococci (coagulase-negative + non-ESBL) |
0.03 |
0.03 |
? － ? |
Clinafloxacin (PD 127391) |
307 |
| Staphylococci (coagulase-negative + non-ESBL) |
0.25 |
0.5 |
? － ? |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
307 |
| Staphylococci (coagulase-negative + oxacillin-resistant) |
>0.12 |
>4 |
0.12 － >4 |
Levofloxacin (Levaquin, Quixin) |
265 |
| Staphylococci (coagulase-negative + oxacillin-resistant) |
>0.12 |
>8 |
≤0.06 － >8 |
Clindamycin (Cleocin) |
265 |
| Staphylococci (coagulase-negative + oxacillin-resistant) |
>0.12 |
>8 |
? － ? |
Clindamycin (Cleocin) |
39 |
| Staphylococci (coagulase-negative + oxacillin-resistant) |
0.25 |
0.25 |
≤0.06 － 0.25 |
Quinupristin/Dalfopristin (Synercid) |
265 |